Entera Bio shares surge 13.79% after-hours as board members and CEO buy company stock.

Entera Bio surged 13.79% in after-hours trading following announcements that several board members, including Chairman Geno J. Germano, and CEO Miranda Toledano, executed open market purchases of the company’s shares. The transactions, disclosed in SEC filings, were conducted at prevailing market prices and followed prior insider buying in December 2025. These purchases, involving multiple directors and key executives, signal strong confidence in the company’s strategic direction and pipeline advancements, including its lead candidate EB613 for osteoporosis. Insider buying has occurred six times in the past year, reinforcing positive sentiment among leadership. The after-hours rally reflects investor interpretation of these transactions as a vote of confidence in Entera Bio’s long-term prospects and clinical development potential.